Blueprint Medicines Corporation (LON:0HOJ)
128.11
-0.05 (-0.04%)
At close: Jun 18, 2025
Blueprint Medicines Revenue
Blueprint Medicines had revenue of $149.41M USD in the quarter ending March 31, 2025, with 55.45% growth. This brings the company's revenue in the last twelve months to $562.12M, up 99.19% year-over-year. In the year 2024, Blueprint Medicines had annual revenue of $508.82M with 104.04% growth.
Revenue (ttm)
$562.12M
Revenue Growth
+99.19%
P/S Ratio
14.15
Revenue / Employee
$866.13K
Employees
649
Market Cap
6.16B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 508.82M | 259.44M | 104.04% |
Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Indivior | 905.57M |
Blueprint Medicines News
- 2 days ago - Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
- 4 days ago - HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC) - Benzinga
- 4 days ago - HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC) - GlobeNewsWire
- 7 days ago - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - Benzinga
- 7 days ago - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PRNewsWire
- 16 days ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 16 days ago - This ASML Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
- 17 days ago - Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines - GlobeNewsWire